Apoptosis inducing lead compounds isolated from marine organisms of potential relevance in cancer treatment

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 768, Issue C, 2014, Pages 84-97

  Beesoo, Rima ^a   Neergheen Bhujun, Vidushi ^a   Bhagooli, Ranjeet ^a   Bahorun, Theeshan ^a  

^a UNIVERSITY OF MAURITIUS   (Mauritius)

Author keywords

Antitumour drugs; Apoptosis; Cancer; Marine natural products

Indexed keywords

EID: 84897364000     PISSN: 00275107     EISSN: 18792871     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2014.03.005     Document Type: Review

References (167)

1. World Health Organisation Cancer (Fact Sheet No. 297) 2008, Retrieved from http://www.who.int/mediacentre/factsheets/fs297/en/ Last accessed 10.10.13.
2. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. 2002, 3:415-428.
3. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 2004, 3:513-519.
4. Maione P., Rossi A., Airoma G., Ferrara C., Castaldo V., Gridelli C. The role of targeted therapy in non-small cell lung cancer. Crit. Rev. Oncol. Hematol. 2004, 51:29-44.
5. Rossi D., Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003, 88:212-218.
6. Sporn M.B. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 1976, 36:2699-2702.
7. Tsao A.S., Kim E.S., Hong W.K. Chemoprevention of cancer. CA Cancer Clin. 2004, 54:150-180.
8. Suppipat K., Shik Park C., Shen Y., Zhu H.D. Lacorazza, sulforaphane induces cell cycle arrest and apoptosis in acute lymphoblastic leukemia cells. PLoS ONE 2012, 7:1-12.
9. Gamet-Payrastre L., Li P., Lumeau S. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000, 60:1426-1433.
10. Quoc Trung L., Espinoza J.L., Takami A.S.N. Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS ONE 2013, 8:1-11.
11. Tsung-Teng H., Hung-Chi L., Chang-Chieh C., Chia-Chen L., Chia-Fong W., Ting-Shu W., Fu-Guo L., Hsin-Chih L. Resveratrol induces apoptosis of human nasopharyngeal carcinoma cells via activation of multiple apoptotic pathways. J. Physiol. 2011, 226:720-728.
12. Xie X., Wang S.S., Wong T.C.S., Fung M.C. Genistein promotes cell death of ethanol-stressed HeLa cells through the continuation of apoptosis or secondary necrosis. Cancer Cell Int. 2013, 13:1-15.
13. George J., Banik N.L., Ray S.K. Genistein induces receptor and mitochondrial pathways and increases apoptosis during Bcl-2 knockdown in human malignant neuroblastoma SK-N-DZ cells. J. Neurosci. 2010, 88:877-886.
14. Shin-Hwar W., Liang-Wen H., Jai-Sing Y., Hung-Yi C., Hui-Yi L., Jo-Hua C., Chi-Cheng L., Jiun-Long Y., Tung-Yuan L., Yang-Ching K., Jing-Gung C. Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways. Anticancer Res. 2010, 30:4379-4390.
15. Chin-Cheng S., Jaung-Geng L., Te-Mao L., Jing-Gung C., Jai-Sing Y., Siu-Wan I., Wen-Chuan L., Guang-Wei C. Curcumin-induced apoptosis of human colon cancer Colo 205 cells through the production of ROS, Ca2+ and the activation of caspase-3. Anticancer Res. 2006, 26:4379-4390.
16. Ozturk G., Ginis Z., Akyol S., Erden G., Gurel A., Akyol O. The anticancer mechanism of caffeic acid phenethyl ester (CAPE): review of melanomas, lung and prostate cancers. Eur. Rev. Med. Pharmacol. Sci. 2012, 16:2064-2068.
17. Masahiko W., Keiichi H., Atsushi T., Nobuyoshi S., Toshio N. Caffeic acid phenethyl ester induces apoptosis by inhibition of NF_B and activation of Fas in human breast cancer MCF-7 cells. J. Biol. Chem. 2003, 13:6017-6025.
18. Bhanot A., Sharma R., Noolvi M.N. Natural sources as potential anti-cancer agents: a review. Phytomedicine 2011, 3:9-26.
19. Schumacher M., Kelkel M., Dicato M., Diederich M. Gold from the sea: marine compounds as inhibitors of the hallmarks of cancer. Biotechnol. Adv. 2011, 29:531-547.
20. Nobili S., Lippi D., Witort E., Donnini M., Bausi L., Minni E., Capaccioli S. Natural compounds for cancer treatment and prevention. Pharmacol. Res. 2009, 59:365-378.
21. Bergmann E., Feeney R.J. The isolation of a new thymine pentoside from sponges. J. Am. Chem. Soc. 1950, 72:2809-2810.
22. Newman D.J., Cragg G.M. Marine natural products and related compound in clinical and advanced preclinical trials. J. Nat. Prod. 2004, 68:1216-1238.
23. Gerwick W.H., Moore B.S. Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. Chem. Biol. 2012, 19:85-98.
24. Hussain S., Fareed S., Ansari S., Khan S. Marine natural products: a lead for Anti-cancer. Indian J. Geo. Mar. Sci. 2012, 41:27-39.
25. Minh C.V., Kiem P.V., Dang N.H. Marine natural products and their potential application in the future. AJST 2005, 22:297-311.
26. Burgess J.G. New and emerging analytical techniques for marine biotechnology. Curr. Opin. Biotechnol. 2012, 23:29-33.
27. Williams D.H., Stone M.J., Hauk P.R., Rahman S.K. Why are secondary metabolites (natural products) biosynthesized. J. Nat. Prod. 1989, 52:1189-1208.
28. Firn R.D., Jones C.G. Natural products: a simple model to explain chemical diversity. Nat. Prod. Rep. 2003, 20:382-391.
29. Simmons T.L., Andrianasolo E., McPhail K., Flatt P., Gerwick W.H. Marine natural products as anticancer drugs. Mol. Cancer Ther. 2005, 4:333-342.
30. Lin X.K., Liu M., Hu C.X., Liao D.J. Targeting cellular proapoptotic molecules for developing anticancer agents from marine sources. Curr. Drug Targets 2010, 11:708-715.
31. Leal M.C., Madeira C., Brandão C.A., Puga J., Calado R. Bioprospecting of marine invertebrates for new natural products-a chemical and zoogeographical perspective. Molecules 2012, 17:9842-9854.
32. Vinothkumar S., Paramewaran P.S. Recent advances in marine drug research. Biotech. Adv. 2013, 31:1826-1845.
33. Mayer A.M.S., Glaser K.B., Cuevas C., Jacobs R.S., Kem W., Little R.D. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol. Sci. 2010, 31:255-265.
34. Reed J.C. Mechanisms of apoptosis. Am. J. Pathol. 2000, 157:1415-1430.
35. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
36. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462.
37. Rowinsky E.K. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J. Clin. Oncol. 2005, 23:9394-9407.
38. Call J.A., Eckhardt S.G., Camidge D.R. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol. 2008, 9:1002-1011.
39. Iannolo G., Conticello C., Memeo L., De Maria R. Apoptosis in normal and cancer stem cells. Crit. Rev. Oncol. Hematol. 2008, 66:42-51.
40. Burz C., Berindan-Neagoe I., Balacescu O., Irimie A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol. 2009, 48:811-821.
41. Fulda S., Pervaiz S. Apoptosis signaling in cancer stem cells. Int. J. Biochem. Cell Biol. 2009, 42:31-38.
42. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 2005, 55:178-194.
43. Eberle J., Fecker L.F., Forschner T., Ulrich C., Röwert-Huber J., Stockfleth E. Apoptosis pathways as promising targets for skin cancer therapy. Br. J. Dermatol. 2007, 156:18-24.
44. Ziegler D.S., Kung A.L. Therapeutic targeting of apoptosis pathways in cancer. Curr. Opin. Oncol. 2008, 20:97-103.
45. Ledgerwood E.C., Morison I.M. Targeting the apoptosome for cancer therapy. Clin. Cancer Res. 2009, 15:420-424.
46. Schwarzenberg K.V., Vollmar A.M. Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy. Cancer Lett. 2010, 332:295-303.
47. Oliver L., Vallette F.M. The role of caspases in cell death and differentiation. Drug Resist. Updat. 2005, 8:163-170.
48. Abe K., Kurakin A., Mohseni-Maybodi M., Kay B., Khosravi-Far R. The complexity of TNF-related apoptosis-inducing ligand. Ann. N. Y. Acad. Sci. 2000, 926:52-63.
49. Ozoren N., El-Deiry W.S. Cell surface death receptor signaling in normal and cancer cells. Semin. Cancer Biol. 2003, 13:135-147.
50. Peter M.E., Krammer P.H. The CD95 (APO-1/Fas) DISC and beyond. Cell Death Differ. 2003, 10:26-35.
51. Thorburn A. Death receptor-induced cell killing. Cell. Signal. 2004, 16:139-144.
52. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
53. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science 1998, 281:1312-1316.
54. Orrenius S., Zhivotovsky B., Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol. 2003, 4:552-565.
55. Roderick H.L., Cook S.J. Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat. Rev. Cancer 2008, 8:361-375.
56. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Disc. 2009, 8:579-591.
57. Riedl S.J., Salvesen G.S. The apoptosome: signalling platform of cell death. Nat. Rev. Mol. Cell Biol. 2007, 8:405-413.
58. Billen L.P., Shamas-Din A., Andrews D.W. Bid: a Bax-like BH3 protein. Oncogene 2008, 1:93-104.
59. Fulda S. Tumor resistance to apoptosis. Int. J. Cancer 2009, 124:511-515.
60. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
61. Okada H., Mak T.W. Pathways of apoptotic and non-apoptotic death in tumor cells. Nat. Rev. Cancer. 2004, 4:592-603.
62. Yip K.W., Reed J.C. Bcl-2 family proteins and cancer. Oncogene 2008, 27:6398-6406.
63. Ghavami S., Hashemi M., Ande S.R., Yeganeh B., Xiao W., Eshraghi M., Bus C.J., Kadkhoda K., Wiechec E., Halayko A.J., Los M. Apoptosis and cancer: mutations within caspase genes. J. Med. Genet. 2009, 46:497-510.
64. Okun K., Balakin V., Tkachenko S.E., Ivachtchenko A.V. Caspase activity modulators as anticancer agents. Anticancer Agents Med. Chem. 2008, 8:322-341.
65. Martelli A.M., Tazzari P.L., Evangelisti C., Chiarini F., Blalock W.L., Billi A.M., Manzoli L., McCubrey J.A., Cocco L. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr. Med. Chem. 2007, 14:2009-2023.
66. Sigel M.M. Food-Drugs from the Sea: Proceedings 1969, 281-294. Marine Technology Society, Washington, DC. H.W. Youngken (Ed.).
67. Schoffski P., Dumez H., Wolter P., Stefan C., Wozniak A., Jimeno J., Van Oosterom A.T. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin. Pharmacother. 2008, 9:1609-1618.
68. Rinehart K.L. Ecteinascidin-729, ecteinascidin-743, ecteinascidin-745, ecteinascidin-759a, ecteinascidin-759b, and ecteinascidin-770-potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinate. J. Org. Chem. 1990, 55:4512-4515.
69. Cuevas C., Francesch A. Development of Yondelis1 (trabectedin, ET-743), a semisynthetic process solves the supply problem. Nat. Prod. Rep. 2009, 26:322-327.
70. Rinehart K.L., Gravalos L.G., Faircloth G. Preclinical antitumor development of a marine derived natural product. Proc. Am. Assoc. Cancer Res. 1995, 36:390.
71. Jimeno J. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs 2004, 15:321-329.
72. Meco D. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother. Pharmacol. 2003, 52:131-138.
73. Takahashi N., Li W.W., Banerjee D., Scotto K.W., Bertino J.R. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin. Cancer Res. 2001, 7:3251-3257.
74. Riccardi A. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs 2005, 16:811-815.
75. Zewail-Foote M., Hurley L.H. Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites. J. Am. Chem. Soc. 2001, 123:6485-6495.
76. Takebayashi Y. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med. 2001, 7:961-966.
77. Soares D.G. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:13062-13067.
78. Herrero A.B. cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006, 66:8155-8162.
79. Erba E. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer 2001, 37:97-105.
80. Atmaca H., Bozhurt E., Uzunoglu S., Uslu R., Karaca B. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells. Toxicol. Lett. 2013, 221:128-136.
81. Donald S. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat. Cancer Res. 2003, 63:5902-5908.
82. Beumer J.H., Schellens J.H., Beijnen J.H. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacol. Res. 2005, 51:391-398.
83. Uemura D. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J. Am. Chem. Soc. 1985, 107:4796-4798.
84. Pettit G.R. Antineoplastic agents. 219. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J. Med. Chem. 1991, 34:3339-3340.
85. Bai R.L., Paull K.D., Herald C.L., Malspeis L., Pettit G.R., Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. 1991, 266:15882-15889.
86. Towle M.J., Salvato K.A., Budrow J., et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001, 61:1013-1021.
87. Dabydeen D.A. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol. Pharmacol. 2006, 70:1866-1875.
88. Kuznetsov G., Towle J.M. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage, by halichondrin B macrocyclic ketone analogue, E 7389. Cancer Res. 2004, 64:5760-5766.
89. Yu M.J. Discovery of E7389, a fully synthetic macrocyclic ketone analog of halichondrin B. Anticancer Agents from Natural Products 2005, 241-265. CRC Press, Taylor and Francis Group, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
90. Jordan M.A., Kamath K., Manna T. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 2005, 4:1086-1095.
91. Okouneva T., Azarenko O., Wilson L., Littlefield B.A., Jordan M.A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 2008, 7:2003-2011.
92. Tan A.R. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15:4213-4219.
93. Pettit G.R. The dolastatins. Fortschr. Chem. Org. Naturst. 1997, 70:1-79.
94. Harrigan G.G., Luesch H., Yoshida W.Y. Symplostatin 1: a dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. J. Nat. Prod. 1998, 61:75-77.
95. Luesch H., Moore R.E., Paul V.J., Mooberry S.L., Corbett T.H. Isolation of dolastatin 10 from the marine cyanobacterium symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J. Nat. Prod. 2001, 64:907-910.
96. Pettit G.R. The isolation and structure of a remarkable marine animal antineoplastic constituent - dolastatin 10. J. Am. Chem. Soc. 1987, 109:6883-6885.
97. Bai R., Pettit G.R., Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangable nucleotide and Vinca alkaloid sites. J. Biol. Chem. 1990, 265:17141-17149.
98. Pettit R. The isolation and structure of a remarkable marine animal antineoplastic constituent - dolastatin 10. J. Am. Chem. Soc. 1987, 100:6883-6885.
99. Pettit G.R. Progress in the discovery of biosynthetic anticancer drugs. J. Nat. Prod. 1996, 59:812-821.
100. Johnson I.S. The vinca alkaloids: a new class of oncolytic agents. Cancer Res. 1963, 23:1390.
101. Schaufelberger D.E. The large-scale isolation of bryostatin-1 from Bugula neritina following current good manufacturing practices. J. Nat. Prod. 1991, 54:1265-1270.
102. Cuadrado A. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J. Biol. Chem. 2003, 278:241-250.
103. Cuadrado A., Gonzalez L., Suarez Y., Martinez T., Munoz A. JNK activation is critical for Aplidin-induced apoptosis. Oncogene 2004, 23:4673-4680.
104. Biscardi M. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acutemmyeloid leukemia. Ann. Oncol. 2005, 16:1667-1674.
105. Mitsiades C.S. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008, 68:5216-5225.
106. Le Tourneau C. Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr. Pharm. Des. 2007, 13:3427-3439.
107. Pettit G.R. The dolastatins. Fortschr. Chem. Org.Naturst. 1997, 70:1-79.
108. Harrigan G.G., Luesch H., Yoshida W.Y. Symplostatin 1: a dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. J. Nat. Prod. 1998, 61:75-77.
109. Krug M., Miller V.A., Kalemkerian G.P. Phase II study of dolastatin-10 in patients with advanced non-small cell lung cancer. Ann. Oncol. 2000, 11:227-228.
110. Hamann M.T., Scheuer P.J. Kahalalide F: a bioactive depsipeptide from the Sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. J. Am. Chem. Soc. 1993, 115:5825-5826.
111. Minami Y. Structure of cypemycin, a new peptide antibiotic. Tetrahedron Lett. 1994, 35:8001-8004.
112. Neuhof T., Hassallidin A. A glycosylated lipopeptide with antifungal activity from the cyanobacterium Hassallia sp. J. Nat. Prod. 2005, 68:695-700.
113. Goetz G., Yoshida W.Y., Scheuer P.J. The absolute stereochemistry of kahalalide F. Tetrahedron 1999, 55:7739-7746.
114. Lopez-Macia A., Jimenez J.C., Royo M., Giralt E., Albericio F. Synthesis and structure determination of kahalalide F (1, 2). J. Am. Chem. Soc. 2001, 123:11398-11401.
115. Janmaat M.L., Rodriguez J.A., Jimeno J., Kruyt F.A., Giaccone G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol. Pharmacol. 2005, 68:502-510.
116. Suarez Y., Gonzalez L., Cuadrado A., Berciano M., Lafarga M., Munoz A., Kahalalide F. A new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol. Cancer Ther. 2003, 2:863-872.
117. Garcia-Rocha M., Bonay P., Avila J. The antitumoral compound kahalalide F acts on cell lysosomes. Cancer Lett. 1996, 99:43-50.
118. Sewell J.M. The mechanism of action of kahalalide F: variable cell permeability in human hepatoma cell lines. Eur. J. Cancer 2005, 41:1637-1644.
119. Ling Y.H. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur. J. Cancer 2009, 45:1855-1864.
120. Morris J.C., Nicholas G.M., Phillips A.J. Marine natural products: synthetic aspects. Nat. Prod. Rep. 2007, 24:87-108.
121. Pettit R. The isolation and structure of a remarkable marine animal antineoplastic constituent - dolastatin 10. J. Am. Chem. Soc 1987, 100:6883-6885.
122. Kortmansky G., Schwartz G.K. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003, 21:924-936.
123. Hornung R.L. Preclinical evaluation of bryostatin as an anticancer agent against several murine cell lines: in vitro and in vivo activity. Cancer Res. 1992, 52:101-107.
124. Ali S., Aranha O., Li Y., Pettit G.R., Sarkar F.H., Philip P.A. Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. Cancer Chemother. Pharmacol. 2003, 52:235-246.
125. Wang S., Wang Z., Boise L.H., Dent P., Grant S. Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia 1999, 13:1564-1573.
126. Varterasian M. Phase I trial of bryostatin 1 in relapsed lymphoma and CLL. Blood 1996, 88:2269.
127. Varterasian M. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Invest. New Drugs 2001, 19:245-247.
128. Varterasian M.L. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin. Cancer Res. 2000, 6:825-828.
129. Grant S. Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin. Cancer Res. 1998, 4:611-618.
130. Clamp A., Jayson G.C. The clinical development of the bryostatins. Anticancer Drugs 2002, 13:676-683.
131. Talpir R., Benayahu Y., Kashman Y., Pannell L., Schleyer M. Hemiasterlin and geodiamolide TA: two new cytotoxic peptides from the marine sponge Hemiasterella minor (Kirkpatrick). Tetrahedron Lett. 1994, 35:4453-4456.
132. Coleman J.E., De Silva E.D., Kong F., Andersen R.J., Allen T.M. Cytotoxic peptides from the marine sponge Cymbastela sp. Tetrahedron 1995, 51:10653-10662.
133. Anderson H.J., Coleman J.E., Andersen R.J., Roberge M. Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother. Pharmacol. 1997, 39:223-226.
134. Kuznetsov G., TenDyke K., Towle M.J., Cheng H., Liu J., Marsh J.P., Schiller S.E.R., Spyvee M.R., Yang H., Seletsky B.M., Shaffer C.J., Marceau V., Yao Y., Suh E., Campagna S., Fang F.G., Kowalczyk J.J., Littlefield B.A. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol. Cancer Ther. 2009, 8:2852-2856.
135. Loganzo F. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 2003, 63:1838-1845.
136. Ratain M.J. Phase 1 and pharmacological study of HTI-286, a novel antimicrotubule agent: correlation of neutropenia with time above a threshold serum concentration. Proc. Am. Soc. Clin. Oncol. 2003, 22:516.
137. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Chem. Int. Ed. Engl. 2003, 42:355-357.
138. Groll M., Huber R., Potts B.C.G. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. Am. Chem. Soc. 2006, 128(April (15)):5136-5141.
139. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A., Ovaa H., Berkers C., Nicholson B., Chao T.H., Neuteboom S.T., Richardson P., Palladino M.A., Anderson K.C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005, 8:407-419.
140. Cusack J.C., Liu R., Xia L., Chao T.H., Pien C., Niu W., Palombella V.J., Neuteboom S.T., Palladino M.A. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin. Cancer Res. 2006, 12:6758-6764.
141. Ruiz S., Krupnik Y., Keating M., Chandra J., Palladino M., Mc Conkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol. Cancer Ther. 2006, 5:1836-1843.
142. Miller C.P., Dujka M.E., McConkey D.J., Munsell M., Palladino M., Chandra J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110:267-277.
143. Fenical W. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 2009, 17:2175-2180.
144. Groll M. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of b-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 2006, 128:5136-5141.
145. Chauhan D. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer 2006, 95:961-965.
146. Ahn K.S., Sethi G., Chao T.H., Neuteboom S.T.C., Chaturvedi M.M., Palladino M.A., Younes A., Aggarwal B.B. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-κB-regulated gene products. Blood 2007, 110:2286-2295.
147. Lam K.S. From natural product to clinical trials: NPI-0052 (salinosporamide A), a marine actinomycete-derived anticancer agent. Natural Products Chemistry for Drug Discovery 2010, 355-373. Royal Society of Chemistry. 18th ed. A.D. Buss, M.S. Butler (Eds.).
148. Pettit G.R., Chicacz Z.A., Gao F., Herald C.L., Boyd M.R., Schmidt J.M., Hooper J.N.A. Antineoplastic agents. Isolation and structure of spongistatin 1. J. Org. Chem. 1993, 58:1302-1304.
149. Bai R., Cichacz Z.A., Herald C.L., Pettit G.R., Hamel E. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol. Pharmacol. 1993, 44:757-766.
150. Schyschka A., Rudy I., Jeremias N., Barth N., Pettit G.R., Vollmar A.M. Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP. Leukemia 2008, 22:1737-1745.
151. Schneiders U.M., Schyschka L., Rudy A., Vollmar A.M. BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells. Mol. Cancer Ther. 2009, 8:2914-2925.
152. Rothmeier A.S., Ischenko I., Joore J., Garczarczyk D., Furst R., Bruns C.J., Vollmar A.M., Zahler S. Investigation of the marine compound spongistatin 1 links the inhibition of PKCalpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis. FASEB J. 2009, 23:1127-1137.
153. De Souza M.V. (+)-Discodermolide: a marine natural product against cancer. Sci. World J. 2004, 4:415-436.
154. Gunasekera S.P., Gunasekera M., Longley R.E., Schulte G.K. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissolute. J. Org. Chem. 1990, 55:4912-4915.
155. Gunasekera S.P., Gunasekera M., Longley R.E., Schulte G.K. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissolute. J. Org. Chem. 1991, 56:1346.
156. Martello L.A., McDaid H.M., Regl D.L., Yang C.P., Meng D., Pettus T.R., Kaufman M.D., Arimoto H., Danishefsky S.J., Smith A.B., Horwitz S.B. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin. Cancer Res. 2000, 6:1978-1987.
157. Khrapunovich-Baine M., Menon V., Verdier-Pinard P., Smith A.B., Angeletti R.H., Fiser A., Horwitz S.B., Xiao H. Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization. Biochem. J. 2009, 48:11664-11677.
158. Broker L.E., Huisman C., Ferreira C.G., Rodriguez J.A., Kruyt F.A., Giaccone G. Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells. Cancer Res. 2002, 62:4081-4088.
159. Molinski T.F., Dalisay D.S., Lievens S.L., Saludes J.P. Drug development from marine natural products. Nat. Rev. Drug Discov. 2009, 8:69-85.
160. Bai R., Pettit G.R., Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol. 1990, 39:1941-1949.
161. Taraboletti G., Poli M., Dossi R., Manenti L., Borsotti P., Faircloth G.T., Broggini M., D'Incalci M., Ribatti D., Giavazzi R. Antiangiogenic activity of aplidine, a new agent of marine origin. Br. J. Cancer 2004, 90:2418-2424.
162. Frei B., Lawson S. Vitamin C and cancer revisited. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11037-11038.
163. Proksch P., Edrada-ebel R., Ebel R. Drugs from the sea - opportunities and obstacles. Mar. Drugs 2003, 1:5-17.
164. Mayer A.M., Gustafson K.R. Marine pharmacology in 2000; antitumor and cytotoxic compounds. Int. J. Cancer. 2003, 105:291-299.
165. Mendola D. Aquacultural Production of Bryostatin 1 and Ecteinascidin 743. Drugs from the Sea 2000, 120-133.
166. Ichiba I., Corgiat J.M., Scheur P.J., Kelly-Borges M. 8-hydroxymanzamine A, a beta-carboline alkaloids from a sponge Pachypellina sp. J Nat Prod 1994, 57:168-170.
167. Faulkner D.J., Harper M.K., Haygood M.G. Symbiotic bacteria in sponges: sources of bioactive substances. Drugs from the Sea 2000, 107-119. S. Karger AG, Basel, Switzerland. N. Fusetani (Ed.).